Physician profile
Monique Crabb
NPI 1326058694
$1,640.76
in general payments reported to CMS, 2019-2025
31 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $58.12 · 2022: $384 · 2023: $361 · 2024: $249 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $233.68 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $191.19 | 2022-2025 | Slynd |
| Abbvie INC. | $128.09 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $105.16 | 2019-2024 | Novasure, Myosure Tissue Removal Device |
| Myriad Women'S Health, INC. | $77.98 | 2023 | Myrisk |
| Aspira Women'S Health INC | $77.65 | 2022-2023 | Ova1 |
| Minerva Surgical, INC | $74.52 | 2019-2024 | |
| Pfizer INC. | $72.84 | 2023-2024 | |
| Biogen, INC. | $71.95 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $65.18 | 2019-2024 | Lynparza, Keytruda |
| Sumitomo Pharma America, INC. | $63.51 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $44.92 | 2020-2022 | |
| Organon LLC | $41.84 | 2022-2023 | Nexplanon |
| Channel Medsystems, INC. | $40.49 | 2022 | |
| Mayne Pharma Commercial LLC | $39.85 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $32.48 | 2019-2023 | Mara Console |
| Bayer Healthcare Pharmaceuticals INC. | $29.92 | 2019 | |
| Amag Pharmaceuticals, INC. | $29.75 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.06 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $21.07 | 2023 | Vivjoa |
| Meditrina | $18.19 | 2023-2024 | |
| Ethicon US, LLC | $17.99 | 2022 | |
| Therapeuticsmd, INC. | $17.84 | 2022 | |
| Lilly USA, LLC | $17.46 | 2024 | Zepbound |
| Millicent US INC | $16.51 | 2025 | Intrarosa, Femlyv |
| Mission Pharmacal Company | $15.69 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2019 | |
| Agile Therapeutics, INC. | $14.68 | 2022 | |
| Duchesnay USA Incorporated | $14.32 | 2019 | |
| Covidien LP | $14.24 | 2020 | |
| Avion Pharmaceuticals | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Crabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.